Truvada (Tenofovir/FTC): Research
- University of South Florida to Join National Study of HIV Prevention Pill in Young Men (January 2, 2013)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Truvada's Efficacy as PrEP Reaffirmed (November/December 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
On TheBodyPRO.com
- Truvada Drug Trials Signal "Turning Point" in AIDS Epidemic (July 13, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Studies Show Success, Highlight Challenges of PrEP Strategy (July 12, 2012)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Global Campaign for Microbicides Statement on the Discontinuation of the FEM-PrEP Trial (April 19, 2011)
From Global Campaign for Microbicides
- Researchers to Wind Down HIV Prevention Trial in Women After Interim Results Find Drug Not Offering Protection From HIV (April 19, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Scientists Halt FEM-PrEP Study in Africa (April 18, 2011)
In Housing Works AIDS Issues Update, from Housing Works
- The FEM-PrEP HIV Prevention Study and Its Implications for NIAID Research (April 18, 2011)
From U.S. National Institute of Allergy and Infectious Diseases
- Results of FEM-PrEP Clinical Trial Examining Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among Heterosexual Women (April 18, 2011)
From U.S. Centers for Disease Control and Prevention
 PrEP Ineffective for Women? Study on Truvada for HIV Prevention Is Unexpectedly Cut Short: A Blog Entry by Myles Helfand (April 18, 2011)
From TheBody.com
- Once-a-Day Truvada Lowers HIV Risk in Gays and Transgender Women (March 2011)
To read PDF, click here.
In HIV Treatment ALERTS!, from The Center for AIDS
On TheBodyPRO.com
- Gilead Sciences Receives "Refuse to File" Notification From U.S. FDA on New Drug Application for Single-Tablet Regimen of Truvada and TMC278 (January 25, 2011)
From Gilead Sciences, Inc.
- iPrEx: A Tenofovir/Emtricitabine Pill a Day Keeps the HIV (Doctor) Away (December 8, 2010)
Part of "Top HIV/AIDS-Related Clinical Developments of 2010," by David Wohl, M.D.
From TheBody.com
- PrEP: What Does It Mean for Women? (December 8, 2010)
From Global Campaign for Microbicides
- Questions and Answers: Global Pre-Exposure Prophylaxis Initiative (iPrEx) Study (December 8, 2010)
From Global Campaign for Microbicides
- Taken Preventively Daily HIV Meds Could Reduce HIV Risk Among Gay, Bisexual Men (November 30, 2010)
From Black AIDS Institute
- Chicago-Based Pre-Exposure Prophylaxis Study Team Responds to Recent iPrEx Study Results (November 29, 2010)
From Project PrEPare
- CDC Statement on Results of iPrEx Trial Examining Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex With Men (November 23, 2010)
From U.S. Centers for Disease Control and Prevention
- Global Campaign for Microbicides Lauds Milestone in HIV Prevention Findings That Daily Use of Anti-Retroviral Protects Against HIV Infection (November 23, 2010)
Results from global iPrEx trial offer hope for those at highest risk of infection.
From Global Campaign for Microbicides
- The Future of PrEP: Questions and Next Steps Following the iPrEx Study Results (November 23, 2010)
From Project Inform
- Daily Oral Antiretroviral Reduces HIV Infection Risk in MSM by 44%, Study Finds (November 23, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
|
Advertisement
|
Email
Glossary
